FAM
AKBA icon

Fred Alger Management’s Akebia Therapeutics AKBA Stock Holding History

Fred Alger Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-67,013
Closed -$244K – 449
2025
Q2 		$244K Buy
+67,013
New +$184K ﹤0.01% 423
2020
Q3 		– Sell
-90,000
Closed -$1.22M – 460
2020
Q2 		$1.22M Buy
90,000
+35,000
+64% +$362K ﹤0.01% 334
2020
Q1 		$417K Buy
+55,000
New +$428K ﹤0.01% 367

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Fred Alger Management's AKBA Position: Q3 2025 in Review

Fred Alger Management sold out of Akebia Therapeutics (AKBA) in Q3 2025, closing a stake of 67,013 shares — an estimated $244K sold.

Fred Alger Management first reported a position in AKBA in Q1 2020 and held it in 3 quarters. The position peaked at $1.22M in Q2 2020. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.

  • Fred Alger Management reported no remaining Akebia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Fred Alger Management sold 67,013 Akebia Therapeutics shares in Q3 2025, an estimated $244K.
  • Fred Alger Management first reported a position in Akebia Therapeutics in Q1 2020 and held it in 3 quarters.
  • Fred Alger Management's Akebia Therapeutics position peaked at $1.22M in Q2 2020.
  • 177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.

Based on Fred Alger Management's 13F filing for Q3 2025, filed 14 Nov 2025.